Future Applications

The same SRC-3 mechanism can be manipulated by small molecules to dramatically improve non-malignant diseases. In preclinical studies, tremendous promise has been shown in:

MI & Heart Failure

SRC-3 stimulator treatment after MI results In >55% reduction in scar volume allowing the heart to preserve function, plus:
❖ Decreased cell death
❖ Decreased inflammatory response
❖ Reparative macrophages
❖ Improved fibrotic remodeling
❖ Increased fibroblast NRF2
expression
❖ Decreased infarct size/progression
❖ Improved cardiac function

Stroke

SRC-3 stimulator treatment after stroke results in 65% improvement in stroke recovery, plus:
❖ Decreased apoptosis
❖ Decreased inflammatory response
❖ Reparative microglia
❖ Decreased scarring
❖ Increased astrocyte NRF2 expression
❖ Decreased infarct size/progression
❖ Improved neurologic function
❖ Increased Treg

Expanded Applications

These same mechanisms that alter gene regulation can be expected to have a similar effect on many non-malignant conditions.
❖ Diseases of fibrosis, eg, interstitial pulmonary fibrosis
❖ Diseases of aberrant wound healing
❖ Selected autoimmune disease
❖ Autoinflammatory diseases
❖ Hypertrophic scar